Herreramcdonough7295

Multiple questionnaires exist to measure glaucoma's impact on quality of life. Selecting the right questionnaire for the research question is essential, as is patients' acceptability of the questionnaire to enable collection of relevant patient-reported outcomes.

Quality of life (QoL) relating to a disease and its treatment is an important dimension to capture. This scoping review sought to identify the questionnaires most appropriate for capturing the impact of glaucoma on QoL.

A literature search of QoL questionnaires used in glaucoma, including patient-reported outcomes measures, was conducted and the identified questionnaires were analysed using a developed quality criteria assessment.

Forty-one QoL questionnaires were found which were analysed with the detailed quality criteria assessment leading to a summary score. This identified the top 10 scoring QoL questionnaires rated by a synthesis of the quality criteria grid, considering aspects such as reliability and reproducibility, and the authors' ng questionnaires used to determine vision related QoL in glaucoma and in the responses elicited was identified. In conclusion, no single existing QoL questionnaire design is suitable for all purposes in glaucoma research, rather we have identified the top 10 from which the questionnaire most appropriate to the study objective may be selected. Development of a new questionnaire that could better distinguish between treatments in terms of vision and treatment-related QoL would be useful that includes the patient perspective of treatment effects as well as meeting requirements of regulatory and health authorities. Future work could involve development of a formal weighting system with which to comprehensively assess the quality of QoL questionnaires used in glaucoma.

Eyes with corneal striae had steeper cornea, induced astigmatism, and higher corneal hysteresis, which implies a relationship between striae, corneal shape, and the cornea's resistance to deformation at low intraocular pressures.

Anterior corneal striae (ACS) are associated with low intraocular pressure (IOP). However, the clinical significance of ACS is unclear. Here, we aim to evaluate differences in eyes with striae compared to eyes without striae.

Adults with ACS (cases) and without ACS (controls) ≥8 weeks after glaucoma surgery with an IOP ≤10▒mmHg were enrolled. Optical coherence tomography and optical biometry were performed. Corneal hysteresis (CH), defined as difference in pressure between corneal indentation and reformation in response to an air jet, was obtained by the ocular response analyzer. Hypotony maculopathy (HM) was defined as optic disc swelling, vascular tortuosity attributed to hypotony, or clinical presence of chorioretinal folds confirmed on OCT.

One-hundred sixteen eyes (76 caility to resist deformations at lower IOP. CH, HM, and axial length shortening were associated independent of IOP.

ACS were associated with a steeper cornea, induced astigmatism, and higher CH, suggesting a relationship between striae, corneal shape, and the cornea's ability to resist deformations at lower IOP. CH, HM, and axial length shortening were associated independent of IOP.

In a trio of prospective studies, the iCare rebound tonometer demonstrated significantly lower test-retest variability than Goldmann tonometry with good inter-operator and inter-device reproducibility, supporting its value in monitoring intraocular pressure changes over time.

To characterize intra- and inter-operator and inter-device reliability of intraocular pressure (IOP) measurements with rebound tonometry ([RT], ic100, iCare USA, Inc, Raleigh, NC).

Three prospective cross-sectional studies were conducted in distinct sample of adult patients with established glaucoma, suspected glaucoma, or no glaucoma at the West Virginia University Eye Institute. Participants in study 1 underwent 5 RT measurements in one randomly-selected eye and 5 Goldmann tonometry measurements in the fellow eye by one operator; intra-operator variability was compared using the F test. In study 2, 3 operators each obtained 3 RT measurements in participants in randomized operator order. In study 3, a single operator collected 3 msurement variability and good inter-operator and -device reproducibility suggest that it can characterize IOP changes over time more robustly than Goldmann tonometry, aiding clinicians in assessing the effectiveness of glaucoma therapy and the consistency of IOP control.

Patients can be quite amenable to using eye drop instillation aids. We should consider recommending these devices to patients who otherwise struggle with drop instillation and medication adherence.

To compare patient acceptance of three commercially available eye drop instillation aids in a diverse tertiary care population.

In this prospective, randomized controlled study, 39 patients being treated with topical antihypertensives were assigned to Arm A (no intervention) or Arm B (AutoDrop®, AutoSqueeze™, or SimplyTouch). Subjects in Arm B were instructed to administer their eye drop with the assigned drop aid at every use for approximately 6 weeks. Satisfaction surveys were administered at 3 and 6 weeks, where patients also reported the number of drops missed.

Thirty-two of 39 subjects completed study participation and full data analysis. Within this total group, 24 subjects were randomized to drop aids (AutoDrop® N=10, AutoSqueeze™ N=8, SimplyTouch N=6), and 8 were randomized to no drop aid. AZD9291 nmr At the 3- more objective data is needed to determine whether these devices would improve medication compliance and clinical outcomes.

The development of beta-zone peripapillary atrophy and focal lamina cribrosa defect was significantly associated with decreased peripapillary optical coherence tomography angiography vessel parameters in young myopic eyes.

To investigate whether beta zone peripapillary atrophy (β-PPA) and focal lamina cribrosa defect (FLD) affect peripapillary vessel density (VD) or perfusion density (PD) from optical coherence tomography angiography (OCTA) in young myopic eyes.

In a cross-sectional study, 330 eyes of 165 healthy volunteers with myopia were involved. Eyes underwent OCTA to measure peripapillary PD and VD. Eyes were grouped according to the presence of β-PPA or FLD eyes without β-PPA or FLD (group A), eyes with β-PPA but without FLD (group B), and eyes with both β-PPA and FLD (group C). PD and VD were compared among three groups, and linear mixed-effect regression model was used to investigate the determinants of PD.

β-PPA was found in 219 eyes (66.4%), and FLD was detected in 27 eyes (8.2%). The average VD and PD were greatest in group A (19.13±2.04▒mm-1 and 0.375±0.038), followed by group B (18.34±2.26▒mm-1 and 0.363±0.042) and group C (16.71±2.81▒mm-1 and 0.330±0.052) (P<0.001). The linear mixed-effect model demonstrated that presence of FLD (P=0.001) or β-PPA (P<0.001), FLD count (P=0.004), and maximal β-PPA width (P<0.001) were significantly associated with average PD after controlling for multiple confounding factors.

Development of β-PPA and FLD, which is closely related with axial elongation in myopic eyes, was significantly associated with reduced OCTA vessel parameters in young myopic eyes. OCTA may help to detect vascular changes and assess glaucoma risk in these eyes.

Development of β-PPA and FLD, which is closely related with axial elongation in myopic eyes, was significantly associated with reduced OCTA vessel parameters in young myopic eyes. OCTA may help to detect vascular changes and assess glaucoma risk in these eyes.

Slow coagulation transscleral cyclophotocoagulation is an effective and safe glaucoma surgery in patients with medically uncontrolled silicone oil-induced glaucoma.

To report the outcomes of slow coagulation continuous wave transscleral cyclophotocoagulation (CW-TSCPC) in patients with medically uncontrolled secondary glaucoma following pars plana vitrectomy (PPV) and intravitreal silicone oil injection (SOI).

This retrospective study enrolled patients with medically uncontrolled glaucoma secondary to PPV with SOI who underwent TSCPC using slow coagulation TSCPC settings (power of 1250 milliwatt and duration of 4▒s). The primary outcome measure was surgical success at 12 months. Surgical success was defined as an IOP 6-21▒mmHg and reduced ≥20% from baseline, no reoperation for glaucoma, and no loss of light-perception vision. Secondary outcome measures included number of glaucoma medications, visual acuity (VA) changes, and surgical complications.

A total of 18 eyes of 18 patients were included in the study. The mean age and follow up of the patients were 51.94±14.5 years and 16.3±3.5 months, respectively. The mean IOP decreased from 29.7±9.6▒mmHg preoperatively to 14.6±6.5▒mmHg at 12 months postoperatively (P<0.001). Glaucoma medications were reduced from 4.2±0.9 at baseline to 1.9±1.3 at 12 months after TSCPC (P<0.001). A non-significant change of logMAR VA was observed at 12 months (P=0.722). The success rate at 12 months was 72.2%. No major complications were reported during the first year of follow-up.

Slow coagulation TSCPC has high efficacy and minimal complications when used as an initial glaucoma surgical procedure in patients with SO-induced glaucoma.

Slow coagulation TSCPC has high efficacy and minimal complications when used as an initial glaucoma surgical procedure in patients with SO-induced glaucoma.

Trabeculectomy can effectively lower IOP. A more junior surgeon profile is emerging. MMC has replaced 5-FU intra-operatively with comparable success rates and a decrease in post-operative antimetabolite administration.

We compare 2-year outcomes for primary trabeculectomy in two cohorts, ten years apart, performed at a large UK teaching hospital.

Consecutive case series of trabeculectomies at Manchester Royal Eye Hospital between 2004-2005(Cohort-1/C1) and 2014-2015(Cohort-2/C2). Pre- and post-operative data was collected for IOP outcomes and complications. Success was defined as IOP ≥6▒mmHg and ≤21▒mmHg, ≤18▒mmHg, ≤16▒mmHg, ≤14▒mmHg or ≤12▒mmHg with/without a ≥20% decrease from pre-operative IOP. Need for and absence of post-operative anti-hypertensive medication defined qualified and complete success respectively.

186 cases were analysed [52(C1),134(C2)]. Mean pre-operative IOP was 24±10▒mmHg(C1), 21±7▒mmHg(C2) (P=0.01). 34 (79%), 33 (77%), 33 (77%), 29 (67%) and 25 (58%) patients in C1 and 88 (70%)U was administered in 54% versus 22% in C1 and C2, respectively(P<0.0001). Needling rates were not statistically different (42%(C1), 54%(C2))(P=0.22).

Trabeculectomy is effective in lowering IOP with success comparable across various definitions. MMC replaced 5-FU as intra-operative antimetabolite resulting in reduced need for post-operative antimetabolite but not increased complications.

Trabeculectomy is effective in lowering IOP with success comparable across various definitions. MMC replaced 5-FU as intra-operative antimetabolite resulting in reduced need for post-operative antimetabolite but not increased complications.

Diplopia was present in ~20% of patients with Ahmed FP7 (FP7) or Baerveldt 350 (B350), compared with 5% to 6% in those with Baerveldt 250 (B250) or controls, suggesting risk of diplopia should be included in preoperative counseling.

The purpose of this study was to examine the prevalence of diplopia and strabismus in patients with B250, B350, or FP7 glaucoma drainage devices (GDD).

In this cohort study, glaucoma patients 18 years and above who had received, or would be receiving, a B250, B350, or FP7 GDD, and medically treated controls were consecutively enrolled from August 8, 2017, through July 31, 2019. The Diplopia Questionnaire was administered ≥30 days postoperatively, and upon enrollment to the controls. All diplopic patients underwent orthoptic measurements, which were reviewed by a strabismus specialist. Patients with GDDs in quadrants other than superotemporal, multiple GDDs, or scleral buckles were excluded. Bonferroni correction was applied for pairwise comparisons.

Diplopia was reported in 23/129 (17.